The US House Judiciary Committee on Thursday voted to approve a fourth bill aimed at tackling high drug prices, approving a measure that would make it easier for biosimilar drugs to come to market, as reported by Yahoo!News.
The panel voted Wednesday to send three related bills to the House floor for consideration.
The four measures were part of a package introduced in April to help generic versions of drugs come to market.
On Wednesday, the committee voted to enable the Federal Trade Commission to ban sham citizen petitions, in which drug companies petition the FDA about a generic company seeking approval for a rival drug to delay its market entry.
The committee also approved a measure to stop product-hopping, the practice of making a minor tweak to the formula of a drug to win a new patent, and another to stop pay-for-delay patent deals.
The bills must now be taken up by the full House and Senate.
To read more NewsPoints articles, click here.